Literature DB >> 26118354

Perfusion SPECT, SISCOM and PET (18)F-FDG in the assessment of drug- refractory epilepsy patients candidates for epilepsy surgery.

M Suárez-Piñera1, A Mestre-Fusco2, M Ley3, S González4, S Medrano4, A Principe3, S Mojal5, G Conesa6, R Rocamora3.   

Abstract

AIMS: Brain perfusion SPECT (ictal-interictal), SPECT images and subtraction ictal SPECT coregistered to MRI (SISCOM) and (18)F-FDG-PET (interictal), play an important role in the pre-surgical diagnosis of patients with medically refractory epilepsy. This study aimed to establish: the reproducibility of visual ictal-interictal SPECT and SISCOM analysis altogether with the capacity of SPECT, SISCOM and PET to determine the epileptogenic zone.
MATERIAL AND METHODS: (99m)Tc-HMPAO SPECT ictal-interictal and SISCOM (Analyze 7.0) were performed on 47 refractory epilepsy patients (24 F, 19-60 yrs). In 13 patients, SISCOM was also performed using a new program (Focus DET). Ictal-interictal SPECT and SISCOM images were analysed independently by two nuclear medicine physicians (observer 1 and 2). Kappa concordance coefficient was used to evaluate the reproducibility. In sixteen patients, SPECT, SISCOM and PET findings were compared with the resected area during the surgery, and surgical outcome using Engel scale or with the stereo EEG-(SEEG).
RESULTS: The ictal-interictal SPECT interobserver agreement was 91%, Kappa index 0.86, SISCOM (Analyze 7.0) interobserver agreement percentage was 82%, Kappa index 0.80, Analyze 7.0 showed a higher inconclusive results than visual SPECT analysis. SISCOM FocusDET interobserver agreement was 92%, Kappa index 0.87, with lower inconclusive results than Analyze 7.0. SPECT, SISCOM and PET combined findings identified 87% seizure onset zone: 79% temporal, 26% parieto-temporal and 7% frontal.
CONCLUSIONS: Ictal-interictal SPECT and SISCOM showed a high reproducibility in this sample of patients with drug-refractory epilepsy. SPECT,SISCOM and PET combined findings improved detection of epileptogenic zone in comparison with the individual assessment.
Copyright © 2015 Elsevier España, S.L.U. and SEMNIM. All rights reserved.

Entities:  

Keywords:  (18)F-FDG-PET; 18F-FDG-PET; Epilepsia; Epilepsy; Ictal-interictal SPECT; SISCOM; SPECT ictal-interictal

Mesh:

Substances:

Year:  2015        PMID: 26118354     DOI: 10.1016/j.remn.2015.05.002

Source DB:  PubMed          Journal:  Rev Esp Med Nucl Imagen Mol        ISSN: 2253-654X            Impact factor:   1.359


  4 in total

1.  Cerebral Hypoperfusion in Hereditary Coproporphyria (HCP): A Single Photon Emission Computed Tomography (SPECT) Study.

Authors:  Guido Valle; Claudio Carmine Guida; Michelangelo Nasuto; Manuela Totaro; Filippo Aucella; Vincenzo Frusciante; Lazzaro Di Mauro; Adele Potenza; Maria Savino; Mario Stanislao; Teresa Popolizio; Giuseppe Guglielmi; Vito Angelo Giagulli; Edoardo Guastamacchia; Vincenzo Triggiani
Journal:  Endocr Metab Immune Disord Drug Targets       Date:  2016       Impact factor: 2.895

2.  Thermography mapping patterns in temporal lobe epilepsy surgery.

Authors:  Enrique de Font-Réaulx; Javier Terrazo Lluch; Ramón López López; Paul Shkurovich Bialik; Miguel Ángel Collado Corona; Luis Guillermo Díaz López; Emilio Arch Tirado; Ernesto Ramírez Navarrete; Adalberto González Astiazarán
Journal:  Surg Neurol Int       Date:  2020-02-28

3.  Localization of irritative zones in epilepsy with thermochromic silicone.

Authors:  Enrique de Font-Réaulx; Javier Terrazo-Lluch; Luis Guillermo Díaz-López; Miguel Ángel Collado-Corona; Paul Shkurovich-Bialik; Adalberto González-Astiazarán
Journal:  Surg Neurol Int       Date:  2022-01-12

4.  Clinical Usefulness of SISCOM-SPM Compared to Visual Analysis to Locate the Epileptogenic Zone.

Authors:  Carla Oliveira Young; Elba C S C Etchbehere; Edna Marina Souza; Sergio Querino Brunetto; Allan de Oliveira Santos; Mariana C L Lima; Sebastian Ortiz-De la Rosa; Marina Alvim; Clarissa Lin Yasuda; Celso Darío Ramos; Fernando Cendes; Barbara Juarez Amorim
Journal:  Front Neurol       Date:  2020-05-29       Impact factor: 4.003

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.